Neuren Pharmaceuticals

Update in progress

NEU.AX (ASX)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on therapies for neurological disorders. It develops DAYBUE (trofinetide) for Rett syndrome in adults and children aged 2 years and older, with a Phase 2 program for Fragile X syndrome. NNZ‑2591 has completed Phase 2 for Phelan–McDermid syndrome and is in Phase 2 for Angelman and Pitt‑Hopkins syndromes, with preclinical work for Prader‑Willi syndrome, Hypoxic Ischemic Encephalopathy and SYNGAP1. Founded in 2001, it is based in Hawthorn East, Australia.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.31; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive